D. Chirnomas

TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements.

J. Ivanovich, P. An, A. Shimamura, 2009, Blood.

Veno‐occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation

W. Saber, C. Duncan, F. Loberiza, 2021, Pediatric blood & cancer.

Prior Gemtuzumab Ozogamicin Exposure in Adults With Acute Myeloid Leukemia Does Not Increase Hepatic Veno-occlusive Disease Risk After Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis.

W. Saber, V. Ho, F. Loberiza, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

Frederick D. Grant, E. Neufeld, Y. Finkelstein, 2009, Blood.

A founder mutation in the TCIRG1 gene causes osteopetrosis in the Ashkenazi Jewish population

N. Treff, B. Rubin, J. Ekstein, 2015, Clinical genetics.

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia

K. Pierce, J. Vermette, C. Abboud, 2018, Leukemia & lymphoma.

Perioperative management of a child with severe hypertension from a catecholamine secreting neuroblastoma

L. Diller, J. W. Sparks, R. Shamberger, 2005, Paediatric anaesthesia.

A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

E. Neufeld, H. Rienhoff, E. Vichinsky, 2011, Haematologica.

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway

A. D’Andrea, T. Taniguchi, R. Kennedy, 2006, Molecular Cancer Therapeutics.

Protein degraders enter the clinic — a new approach to cancer therapy

C. Crews, K. Hornberger, D. Chirnomas, 2023, Nature Reviews Clinical Oncology.

The palatability and tolerability of deferasirox taken with different beverages or foods

E. Vichinsky, S. Goldberg, C. Paley, 2013, Pediatric Blood & Cancer.

Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

R. Gedrich, S. Hurvitz, L. Vahdat, 2022, Cancer Research.